# GLP-1 Users Face Higher Heat-Related Health Risks During Summer
People taking GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) need to take extra precautions in hot weather. These medications increase vulnerability to heat-related illness through multiple mechanisms.
GLP-1 drugs slow gastric emptying, meaning food moves through the stomach more slowly. This slows overall hydration and electrolyte absorption at a time when the body needs fluids most. The medications also reduce thirst signals by affecting appetite-regulating hormones in the brain. Users may not feel thirsty even as they become dangerously dehydrated.
Heat stress compounds these effects. When core body temperature rises, the body relies on sweating to cool down. But dehydration limits sweating capacity. GLP-1 users in summer heat face escalating risk of heat exhaustion and heat stroke, conditions that can cause organ damage or death.
Endocrinologists and cardiologists advise users to drink water consistently throughout the day rather than waiting for thirst cues. Eating electrolyte-rich foods like coconut water, sports drinks, and salty snacks helps replace minerals lost through perspiration. Spending time in air-conditioned spaces during peak heat hours reduces core body temperature stress.
Weight loss from GLP-1 medications also reduces insulating body fat, making temperature regulation harder. Combined with the drug's direct effects on hydration and thermoregulation, this creates a three-pronged problem.
Users should monitor themselves for heat exhaustion symptoms: dizziness, rapid heartbeat, nausea, weakness, or excessive fatigue. Seek immediate medical attention if symptoms worsen or include confusion or loss of consciousness.